Barclays analyst Peter Lawson raised the firm’s price target on Kura Oncology to $32 from $30 and keeps an Overweight rating on the shares. The analyst is encouraged by Kura’s initial combination data showing an improved safety profile for ziftomenib and clinical activity in NPM1 and now KMT2Ar patients. The firm increased its probability of success for Kura’s ziftomenib in the KMT2Ar patient subset of acute myeloid leukemia.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KURA:
- Kura Oncology’s KOMET-007 Trial Shows Promising Results
- Kura Oncology to hold a virtual investor event
- Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
- Kura Oncology reports preliminary ziftomenib combination data
- Kura Oncology Announces Private Placement Details
